2013-02-26 14:33:30 -
Company works with leading pharmaceutical organizations to advance asthma
research
PHILADELPHIA, February 26, 2013 - The Intellectual Property & Science business
of Thomson Reuters, the world's leading provider of intelligent information for
businesses and professionals, today announced the launch of MetaMiner(TM)
Asthma, the latest industry-academic-government, disease-focused collaboration
dedicated to advancing the understanding of pathological pathways that cause
asthma and the development of novel patient profiling methods to improve the
diagnosis and treatment for asthmatic patients.
"Thomson Reuters is delighted to announce its MetaMiner Asthma Partnership
program, bridging two of the top 10 pharmaceutical companies with academic and
government excellence in asthma disease understanding and treatment", said Jon
Brett-Harris, managing director of Life Sciences at Thomson Reuters. "This
program creates a venue for participating organizations to collaborate together
and
with the Thomson Reuters team of systems biology experts in the curation of
disease pathways and development of computational methods to advance treatments
for asthmatics."
MetaMiner Asthma will provide unique insight into the pathological mechanisms
underlying asthma, including the different cell types involved in the disease.
The result of this partnership will add to the currently available collection of
respiratory maps by producing over 30 new pathway maps related to the signaling
of immune cells involved in asthma pathology, such as T-cells, macrophages,
eosinophils and neutrophils. These maps and the insights from computational
analyses using the pathways will be exclusively available to participating
members for the first year, in order to aid in asthma research and protect
intellectual property interests.
The asthma pathway maps will be delivered via MetaCore(TM), the world's most
comprehensive, knowledge-based platform for data mining and functional biology-
related analysis. The content can be used for target discovery, candidate
selection, biomarker discovery, translational medicine and personalized care
applications.
MetaMiner Asthma is the most recent phase of the MetaMiner Respiratory Disease
program, which also includes MetaMiner COPD (Chronic Obstructive Pulmonary
Disease). "MetaMiner Disease Partnerships for asthma and COPD will result in
approximately 150 maps; this is an unprecedented disease-pathology development
that will help industry players, academic researchers, government policy makers,
and payers to develop new diagnostics and treatments for asthma, faster," said
Mr. Brett-Harris.
Learn more about the MetaMiner Disease Partnership program.
Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for
businesses and professionals. We combine industry expertise with innovative
technology to deliver critical information to leading decision makers in the
financial and risk, legal, tax and accounting, intellectual property and science
and media markets, powered by the world's most trusted news organization. With
headquarters in New York and major operations in London and Eagan, Minnesota,
Thomson Reuters employs approximately 60,000 people and operates in over 100
countries. For more information, go to www.thomsonreuters.com.
CONTACT
Jen Breen
Thomson Reuters
jennifer.breen@thomsonreuters.com
+1 215 823 1791
Abbey Anderson
Thomson Reuters
abbey.anderson@thomsonreuters.com
+ 1 215 823 1894
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Thomson Reuters Corporation via Thomson Reuters ONE
[HUG#1681009]
